Magstim Logo

GROUNDBREAKING STUDY: After TMS treatment, 65.3% of Veterans with co-morbid PTSD and MDD demonstrated clinically meaningful reduction

In the largest study of its kind to date, medical researchers with the U.S. Department of Veterans Affairs (VA) supports the effectiveness and safety of transcranial magnetic stimulation for veterans with MDD and PTSD using standard clinical approaches. As published in the Journal of Affective Disorders, “of the 770 who received at least one session, TMS was associated with clinically meaningful (Cohen‚Äôs d>1.0) and statistically significant (all p<.001) reductions in MDD and PTSD. Of the 340 veterans who received an adequate dose, MDD response and remission rates were 41.4% and 20%, respectively. In veterans with co-morbid PTSD, 65.3% demonstrated clinically meaningful reduction and 46.1% no longer met PTSD threshold criteria after TMS. Side effects were consistent with the known safety profile of TMS. VA researchers studied its effectiveness in 770 U.S. military veterans who had been diagnosed with a major depressive disorder‚Äď68% also had post-traumatic stress disorder.” 1

1 Michelle R. Madore F. Andrew Kozel, et al. Prefrontal transcranial magnetic stimulation for depression in US military veterans ‚Äď A naturalistic cohort study in the veterans health administration.

Keep up to date

By signing up you are confirming that you have read, understood and accept our Privacy Policy